FUNDAMENTAL AND CLINICAL STUDIES ON LATAMOXEF IN THE PERINATAL PERIOD

Fundamental and clinical studies on latamoxef (LMOX) in the perinatal period were carried out, and following results were obtained. 1. Concentration of LMOX was showed high peak levels in maternal serum, umbilical serum and amniotic fluid. LMOX seemed to be a very transferable compound to human tiss...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1984/06/25, Vol.37(6), pp.991-1005
Main Authors: TAKASE, ZENJIRO, KOHMOTO, YOSHIYUKI, SHIRAFUJI, HIROKO, SHIMIZU, TETSUYA, ISHIKAWA, MUTSUO, SAKURABA, MAMORU, ICHINOHE, KIHYOE, SUGAHARA, SUGURU, HAYASHI, HIROSHI, CHO, NANKUN, SUZUKI, HIDENOBU, AKIYAMA, TOSHIO, KAWAMURA, EIICHI, TOGO, MITSUMASA, NISHIMOTO, SEKIO, HIDAKA, TERUO, FUKUNAGA, KANGO, KUNII, KATSUAKI, MATSUDA, SEIJI, KASHIWAKURA, TAKASHI, NOJIMA, MICHIO, TAKASE, SACHIKO, NINOMIYA, KEIU, HASEGAWA, YUKIO, NODA, KATSUMI, HAYASAKI, MOTOKI, TAKADA, YASUHIRO, KONDOH, HIDEAKI, ITOH, KUNIHIKO, IIDA, MITSUO, CHIN, CHOKEN, YAMADA, YOSHITAKA, OHSUGI, SATORU, KATOH, RYUHJI, LIN, YIHUNG, BABA, YOSHITAKA, WAKITA, KATSUJI, OKADA, HIROJI, YAMAMOTO, TAKAO, YASUDA, JINSUKE, KANAO, MASAAKI, MOTOMURA, RYUTARO
Format: Article
Language:Japanese
Subjects:
Adult
Amniotic Fluid - analysis
Female
Fetal Blood - analysis
Humans
Infant, Newborn
Infusions, Parenteral
Injections, Intravenous
Maternal-Fetal Exchange
Moxalactam - blood
Moxalactam - therapeutic use
Pregnancy
Pregnancy Complications, Infectious - blood
Pregnancy Complications, Infectious - drug therapy
Puerperal Infection - blood
Puerperal Infection - drug therapy
Pyelonephritis - blood
Pyelonephritis - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fundamental and clinical studies on latamoxef (LMOX) in the perinatal period were carried out, and following results were obtained. 1. Concentration of LMOX was showed high peak levels in maternal serum, umbilical serum and amniotic fluid. LMOX seemed to be a very transferable compound to human tissues. 2. LMOX was administered to 28 cases of various perinatal infections. Clinical responses were excellent in 13 cases, good in 15 cases and poor in none. And 140 cases of prophylactic use in the field of perinatal period were evaluated in good. 3. No side effect was seen and an abnormal laboratory finding, the increase of GPT, was observed in only 1 case. 4. LMOX was a highly useful antibiotic in perinatal infections, the safe dose range of LMOX into the perinatal mothers was estimated to be 2g/day, with the maximum safe dose being 4g/day.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.37.991